PMC:7228307 / 0-609 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1","span":{"begin":33,"end":37},"obj":"Gene"},{"id":"21","span":{"begin":583,"end":587},"obj":"Gene"},{"id":"22","span":{"begin":164,"end":169},"obj":"Species"}],"attributes":[{"id":"A1","pred":"tao:has_database_id","subj":"1","obj":"Gene:2213"},{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"Gene:2213"},{"id":"A22","pred":"tao:has_database_id","subj":"22","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs\nFcγR and mAb immune therapy\nAM Chenoweth et al.\n\nAbstract\nAbstract\nThe human fragment crystallizable (Fc)γ receptor (R) interacts with antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector sys"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":15,"end":28},"obj":"Body_part"},{"id":"T2","span":{"begin":246,"end":260},"obj":"Body_part"},{"id":"T3","span":{"begin":261,"end":266},"obj":"Body_part"},{"id":"T4","span":{"begin":262,"end":264},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma9825"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs\nFcγR and mAb immune therapy\nAM Chenoweth et al.\n\nAbstract\nAbstract\nThe human fragment crystallizable (Fc)γ receptor (R) interacts with antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector sys"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":15,"end":28},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0002405"}],"text":"Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs\nFcγR and mAb immune therapy\nAM Chenoweth et al.\n\nAbstract\nAbstract\nThe human fragment crystallizable (Fc)γ receptor (R) interacts with antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector sys"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":121,"end":123},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0020320"}],"text":"Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs\nFcγR and mAb immune therapy\nAM Chenoweth et al.\n\nAbstract\nAbstract\nThe human fragment crystallizable (Fc)γ receptor (R) interacts with antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector sys"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":15,"end":28},"obj":"http://purl.obolibrary.org/obo/UBERON_0002405"},{"id":"T2","span":{"begin":33,"end":35},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T3","span":{"begin":66,"end":67},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T4","span":{"begin":93,"end":95},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T5","span":{"begin":164,"end":169},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T6","span":{"begin":195,"end":197},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T7","span":{"begin":283,"end":291},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T8","span":{"begin":305,"end":306},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T9","span":{"begin":583,"end":585},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs\nFcγR and mAb immune therapy\nAM Chenoweth et al.\n\nAbstract\nAbstract\nThe human fragment crystallizable (Fc)γ receptor (R) interacts with antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector sys"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":228,"end":235},"obj":"Chemical"},{"id":"T2","span":{"begin":267,"end":274},"obj":"Chemical"},{"id":"T3","span":{"begin":356,"end":364},"obj":"Chemical"},{"id":"T4","span":{"begin":597,"end":605},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_52214"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"}],"text":"Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs\nFcγR and mAb immune therapy\nAM Chenoweth et al.\n\nAbstract\nAbstract\nThe human fragment crystallizable (Fc)γ receptor (R) interacts with antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector sys"}

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T1","span":{"begin":246,"end":260},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"},{"id":"T2","span":{"begin":262,"end":264},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A1","pred":"meddra_id","subj":"T1","obj":"http://purl.bioontology.org/ontology/MEDDRA/10021496"},{"id":"A2","pred":"meddra_id","subj":"T2","obj":"http://purl.bioontology.org/ontology/MEDDRA/10021496"}],"text":"Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs\nFcγR and mAb immune therapy\nAM Chenoweth et al.\n\nAbstract\nAbstract\nThe human fragment crystallizable (Fc)γ receptor (R) interacts with antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector sys"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T1","span":{"begin":38,"end":46},"obj":"http://purl.obolibrary.org/obo/BFO_0000034"},{"id":"T2","span":{"begin":340,"end":344},"obj":"http://purl.obolibrary.org/obo/IDO_0000531"},{"id":"T3","span":{"begin":365,"end":374},"obj":"http://purl.obolibrary.org/obo/BFO_0000034"},{"id":"T4","span":{"begin":437,"end":446},"obj":"http://purl.obolibrary.org/obo/IDO_0000528"}],"text":"Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs\nFcγR and mAb immune therapy\nAM Chenoweth et al.\n\nAbstract\nAbstract\nThe human fragment crystallizable (Fc)γ receptor (R) interacts with antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector sys"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"1","span":{"begin":33,"end":37},"obj":"Gene"},{"id":"21","span":{"begin":583,"end":587},"obj":"Gene"},{"id":"22","span":{"begin":164,"end":169},"obj":"Species"}],"attributes":[{"id":"A1","pred":"pubann:denotes","subj":"1","obj":"Gene:2213"},{"id":"A21","pred":"pubann:denotes","subj":"21","obj":"Gene:2213"},{"id":"A22","pred":"pubann:denotes","subj":"22","obj":"Tax:9606"}],"text":"Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs\nFcγR and mAb immune therapy\nAM Chenoweth et al.\n\nAbstract\nAbstract\nThe human fragment crystallizable (Fc)γ receptor (R) interacts with antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector sys"}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T1","span":{"begin":164,"end":169},"obj":"Species"}],"attributes":[{"id":"A1","pred":"ncbi_taxonomy_id","subj":"T1","obj":"NCBItxid:9606"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs\nFcγR and mAb immune therapy\nAM Chenoweth et al.\n\nAbstract\nAbstract\nThe human fragment crystallizable (Fc)γ receptor (R) interacts with antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector sys"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":92},"obj":"Sentence"},{"id":"T2","span":{"begin":93,"end":120},"obj":"Sentence"},{"id":"T3","span":{"begin":121,"end":140},"obj":"Sentence"},{"id":"T4","span":{"begin":142,"end":150},"obj":"Sentence"},{"id":"T5","span":{"begin":151,"end":159},"obj":"Sentence"},{"id":"T6","span":{"begin":160,"end":447},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs\nFcγR and mAb immune therapy\nAM Chenoweth et al.\n\nAbstract\nAbstract\nThe human fragment crystallizable (Fc)γ receptor (R) interacts with antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector sys"}

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T1","span":{"begin":15,"end":28},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0002405"}],"text":"Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs\nFcγR and mAb immune therapy\nAM Chenoweth et al.\n\nAbstract\nAbstract\nThe human fragment crystallizable (Fc)γ receptor (R) interacts with antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector sys"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T1","span":{"begin":15,"end":28},"obj":"Body_part"},{"id":"T2","span":{"begin":246,"end":260},"obj":"Body_part"},{"id":"T3","span":{"begin":261,"end":266},"obj":"Body_part"},{"id":"T4","span":{"begin":262,"end":264},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma9825"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs\nFcγR and mAb immune therapy\nAM Chenoweth et al.\n\nAbstract\nAbstract\nThe human fragment crystallizable (Fc)γ receptor (R) interacts with antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector sys"}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":92},"obj":"Sentence"},{"id":"T2","span":{"begin":93,"end":120},"obj":"Sentence"},{"id":"T3","span":{"begin":121,"end":140},"obj":"Sentence"},{"id":"T4","span":{"begin":142,"end":150},"obj":"Sentence"},{"id":"T5","span":{"begin":151,"end":159},"obj":"Sentence"},{"id":"T6","span":{"begin":160,"end":447},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs\nFcγR and mAb immune therapy\nAM Chenoweth et al.\n\nAbstract\nAbstract\nThe human fragment crystallizable (Fc)γ receptor (R) interacts with antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector sys"}